ClinicalTrials.gg
TerminatedNCT05090566Updated Apr 24, 2026Results posted

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

A Phase 2 interventional study of Elranatamab + Nirogacestat and Elranatamab + lenalidomide + dexamethasone in Multiple Myeloma, sponsored by Pfizer. Terminated at 25 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.

Enrollment
20th of 31
46 · median 75
Started
2021
with 5 others
Phase 2
18 of 31
12 open now
Registered
6th of 31
by date
Lead sponsor
13 of 31
Pfizer

Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 20th largest by enrollment, is one of 6 that started in 2021, is one of 18 in phase 2, and was the 6th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About elranatamab

elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing elranatamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • PF-06863135, Multiple Myeloma, BCMA, elranatamab, bispecific antibody, MagnetisMM-4
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • multiple myeloma with at least 3
  • Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody
  • defined by at least one of the following:

    1. Serum M-protein >/= 0.5 g/dL by SPEP
    2. Urinary M-protein excretion >/= 200 mg/24 hours by UPEP
    3. Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
  • performance status 0 -1
  • Resolved acute effects of any prior therapy to baseline severity or Grade \</= 1

Exclusion criteria

Exclusion Criteria:

  • Active plasma cell leukemia
  • Amyloidosis
  • Stem cell transplant with 12 weeks prior to enrollment, or active
  • POEMS syndrome
  • Any active uncontrolled bacterial, fungal, or viral infection
  • Impaired cardiovascular function or cardiovascular diseases within 6 months prior to enrollment
  • Previous administration with an drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
  • Sub-Study A Only: Previous treatment with BCMA bispecific antibody
  • Sub-Study B Only: Previous treatment with BCMA directed therapy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Sub-Study A

    BCMA-CD3 bispecific antibody + gamma secretase inhibitor

    Drug: Elranatamab + Nirogacestat

  • Experimental
    Sub-Study B

    BCMA-CD3 bispecific antibody + immunomodulatory drug

    Drug: Elranatamab + lenalidomide + dexamethasone

Interventions

  • DrugElranatamab + Nirogacestat

    Drug pages: Elranatamab · Nirogacestat

    BCMA-CD3 bispecific antibody + gamma secretase inhibitor

    Also known as: PF-06863135, Ogsiveo

  • DrugElranatamab + lenalidomide + dexamethasone

    Drug pages: Elranatamab · Lenalidomide · Dexamethasone

    BCMA-CD3 bispecific antibody + immunomodulatory

    Also known as: PF-06863135; Revlimid

06

What researchers measure

Primary outcomes

  1. SSA: Number of Participants With Dose Limiting Toxicities (DLTs)- Phase 1b Dose Escalation

    DLT- Hematological:Grade (G)4 neutropenia \>5 days; febrile neutropenia; G\>=3 neutropenia, infection; G4 thrombocytopenia; G3 thrombocytopenia and G\>=2 bleeding. Non-hematological: G\>=4 adverse events(AEs); G3 cytokine release syndrome(CRS) \[except CRS not been maximally treated or improved to G\<=1 in 48 hours\]; G3 AEs (except AEs attributed to CRS, G3 nausea, vomiting, diarrhea that improve to G2\<=72 hours after maximal medical management has been initiated, G3 fatigue \< 1 week); confirmed drug-induced liver injury meeting Hy's law criteria; G3-4 laboratory abnormalities(except not associated with clinical sequelae and improve to G=\<2 in 72 hours); G2 clinically important/persistent AEs(cause significant dose delay/reduction) may be DLT; G3 injection site reaction, allergic reaction, anaphylaxis. Common Terminology Criteria for Adverse Events(CTCAE) version 5.0: G1:mild AE, G2:moderate, G3:severe, G4:life-threatening consequences; urgent intervention indicated, G5:death related to AE.

    Time frame: From Cycle 0 Day 1 through Cycle 1 Day 28 (approximately up to 35 days)

  2. SSB: Number of Participants With DLTs- Phase 1b

    Hematological: G4 neutropenia \>5 days; febrile neutropenia; G\>=3 neutropenia with infection; G4 thrombocytopenia; G3 thrombocytopenia with G\>=2 bleeding. Non-hematological: G\>=4 AEs; G3 CRS (except CRS events: not been maximally treated or improved to grade \<=1 within 48 hours); G3 AEs (except: AEs attributed to CRS, G3 nausea, vomiting and diarrhea that improve to G2\<=72 hours after maximal medical management has been initiated, G3 fatigue \< 1 week); confirmed drug-induced liver injury meeting Hy's law criteria; G 3-4 laboratory abnormalities (except: not associated with clinical sequelae and improve to G=\<2 within 72 hours); Other clinically important/persistent AEs (that cause significant dose delay/reduction) may be DLT; G3 injection site reaction. CTCAE version 5.0: G1: Mild AE, G2: Moderate, G3: Severe, G4: Life-threatening consequences; urgent intervention indicated, G5: Death related to AE.

    Time frame: From Cycle 0 Day 1 through Cycle 1 Day 28 (approximately up to 42 days)

Secondary outcomes

  1. SSA: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Related TEAEs- Phase 1b

    An adverse event was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention, including both serious and all non-serious adverse events. A serious adverse event (SAE): any untoward medical occurrence that, at any dose resulting in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. Relatedness of any AE to treatment to be judged by investigator.

    Time frame: From treatment initiation till study completion

  2. SSA: Number of Participants With Severity of AEs According to Cytokine Release Syndrome (CRS) Graded According to American Society for Transplantation and Cellular Therapy (ASTCT) Grading Criteria 2019- Phase 1b

    CRS: supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms must include fever at the onset, and may include hypotension, hypoxia and end organ dysfunction. As per ASTCT criteria, G1: fever (temperature \>=38 degree Celsius), hypotension and/or hypoxia none; G2: fever, hypotension not requiring vasopressors, hypoxia requiring low-flow nasal cannula/facemask or blow-by; G3: fever, hypotension requiring a vasopressor with or without vasopressin, hypoxia requiring high-flow nasal cannula/facemask, nonrebreather mask, or Venturi mask; G4: fever, hypotension requiring multiple vasopressors (excluding vasopressin), hypoxia requiring positive pressure. Organ toxicities associated with CRS graded according to CTCAE v5.0. G1: mild, G2: moderate, G3: severe, G4: life-threatening consequences; urgent intervention indicated. G5: death related to AE.

    Time frame: From treatment initiation till study completion

  3. SSA: Number of Participants With Severity of AEs According to Immune Effector Cell-associated Neurotoxicity Syndrome ICANS Graded According to ASTCT Grading Criteria 2019- Phase 1b

    ASTCT for ICANS \[immune effector cell-associated encephalopathy (ICE, overall score range 0-10, higher score = better condition). G1: ICE score 7-9, awakens spontaneously; G2: ICE score 3-6, awakens to voice; G3: ICE score 0-2, awakens only to tactile stimulus, any clinical seizure that resolves rapidly or non-convulsive seizures on electroencephalography that resolve with intervention, focal/local oedema on neuroimaging; G4: ICE score 0 (unarousable and unable to perform ICE), unarousable or requires vigorous or repetitive tactile stimuli to arouse. Stupor or coma, life-threatening prolonged seizure (\>5 min); or repetitive clinical or electrical seizures without return to baseline in between, deep focal motor weakness such as hemiparesis or paraparesis, diffuse cerebral oedema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI (abducens nerve) palsy; or papilledema; or Cushing's triad; G5: death.

    Time frame: From treatment initiation till study completion

  4. SSA: Number of Participants With Laboratory Abnormalities- Phase 1b

    Number of participants with laboratory abnormalities will be reported in this outcome measure.

    Time frame: From treatment initiation till study completion

  5. SSA: Objective Response Rate (ORR) as Per International Myeloma Working Group (IMWG) Criteria as Determined by Investigator- Phase 1b

    ORR: % of participants with objective response. Stringent complete response(sCR): CR \& normal serum free light chain (sFLC) ratio \&absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence. CR: negative immunofixation on serum \&urine, disappearance of soft tissue plasmacytomas \&\<5% plasma cells in BMA. If disease measurable by sFLC only, preceding criteria \&normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein \& urine M-protein level \<100 mg/24h; PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90% or to \<200 mg/24 hours (If disease measurable by sFLC only: VGPR \& PR: \>=90% \&\>=50% decrease in difference respectively between involved \& uninvolved sFLC levels). In addition, if present at baseline, VGPR \& PR: \>=90% \&\>=50% reduction compared with baseline in soft tissue plasmacytomas' size.

    Time frame: From treatment initiation till study completion

  6. SSA: Complete Response Rate (CRR) as Per IMWG Criteria as Determined by Investigator- Phase 1b

    CRR was defined as the percentage of participants with a Best Overall Response (BOR) of confirmed sCR/CR per IMWG response criteria as determined by investigator. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).

    Time frame: From treatment initiation till study completion

  7. SSA: Time to Response (TTR) as Per IMWG Criteria as Determined by Investigator-Phase 1b

    TTR was defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

    Time frame: From treatment initiation till study completion

  8. SSA: Duration of Response (DOR) as Per IMWG Criteria as Determined by Investigator- Phase 1b

    DOR (for participants (pts) with objective response (OR) per IMWG)=time from the first OR that is confirmed (conf), until conf PD per IMWG, or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest conf response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a prior lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

    Time frame: From treatment initiation till study completion

  9. SSA: Duration of Complete Response (DOCR) as Per IMWG Criteria as Determined by Investigator- Phase 1b

    DOCR (for participants (pts) with CR/sCR per IMWG)= time from the first CR/sCR that is confirmed (conf), until conf PD per IMWG, or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest conf response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a prior lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

    Time frame: From treatment initiation till study completion

  10. SSA: Progression Free Survival (PFS) as Per IMWG Criteria as Determined by Investigator- Phase 1b

    PFS=time from date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest confirmed response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a previous lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

    Time frame: From treatment initiation till study completion

  11. SSA: Overall Survival (OS)- Phase 1b

    OS was defined as the time from the first date of the study intervention to the date of death due to any cause. Participants not known to have died are censored on the date of last known alive.

    Time frame: From treatment initiation till study completion

  12. SSA: Minimal Residual Disease (MRD) Negativity Rate as Per IMWG Criteria- Phase 1b

    MRD negativity rate is defined as the proportion of participants with CR or better by investigator and negative MRD (assessed by central lab) per IMWG sequencing criteria at any time from the date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy, whichever occurs first. 1) CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65; 2) Sequencing MRD-negative: Absence of clonal plasma cells by next generation sequencing (NGS) on BMA in which presence of a clone was defined as \<2 identical sequencing reads obtained after DNA sequencing of BMA using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10\^5 nucleated cells.

    Time frame: From treatment initiation till study completion

  13. SSA: Pre- and Post-dose Concentrations of Elranatamab- Phase 1b

    Time frame: From treatment initiation till study completion

  14. SSA: Trough Serum Concentrations of Nirogacestat- Phase 1b

    Time frame: From treatment initiation till study completion

  15. SSA: Number of Participants With Anti-drug Antibodies (ADA)- Phase 1b

    Time frame: From treatment initiation till study completion

  16. SSA: Number of Participants With Neutralizing Antibodies (NAb)- Phase 1b

    Time frame: From treatment initiation till study completion

  17. SSB: Number of Participants With TEAEs and Treatment Related TEAEs- Phase 1b

    AE: any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention, including both serious and all non-serious adverse events. A SAE: any untoward medical occurrence that, at any dose resulting in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. Relatedness of any AE to treatment to be judged by investigator.

    Time frame: From treatment initiation till study completion

  18. SSB: Number of Participants With Severity of Adverse Events According to CRS Graded According to ASTCT Grading Criteria 2019- Phase 1b Dose Escalation

    CRS: supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms must include fever at the onset, and may include hypotension, hypoxia and end organ dysfunction. As per ASTCT criteria, G1: fever (temperature \>=38 degree Celsius), hypotension and/or hypoxia none; G2: fever, hypotension not requiring vasopressors, hypoxia requiring low-flow nasal cannula/facemask or blow-by; G3: fever, hypotension requiring a vasopressor with or without vasopressin, hypoxia requiring high-flow nasal cannula/facemask, nonrebreather mask, or Venturi mask; G4: fever, hypotension requiring multiple vasopressors (excluding vasopressin), hypoxia requiring positive pressure. Organ toxicities associated with CRS graded according to CTCAE v5.0. G1: mild, G2: moderate, G3: severe, G4: life-threatening consequences; urgent intervention indicated. G5: death related to AE.

    Time frame: From treatment initiation till study completion

  19. SSB: Number of Participants With Severity of Adverse Events According to ICANS Graded According to ASTCT Grading Criteria 2019- Phase 1b Dose Escalation

    ASTCT for ICANS (ICE, overall score range 0-10, higher score = better condition). G1: ICE score 7-9, awakens spontaneously; G2: ICE score 3-6, awakens to voice; G3: ICE score 0-2, awakens only to tactile stimulus, any clinical seizure that resolves rapidly or non-convulsive seizures on electroencephalography that resolve with intervention, focal/local oedema on neuroimaging; G4: ICE score 0 (unarousable and unable to perform ICE), unarousable or requires vigorous or repetitive tactile stimuli to arouse. Stupor or coma, life-threatening prolonged seizure (\>5 min); or repetitive clinical or electrical seizures without return to baseline in between, deep focal motor weakness such as hemiparesis or paraparesis, diffuse cerebral oedema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI (abducens nerve) palsy; or papilledema; or Cushing's triad; G5: death.

    Time frame: From treatment initiation till study completion

  20. SSB: Number of Participants With Laboratory Abnormalities- Phase 1b Dose Escalation

    Number of participants with laboratory abnormalities will be reported in this outcome measure.

    Time frame: From treatment initiation till study completion

  21. SSB: ORR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

    ORR: % of participants with objective response. sCR: CR \& normal sFLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence. CR: negative immunofixation on serum and urine, disappearance of soft tissue plasmacytomas \&\<5% plasma cells in BMA. If disease measurable by sFLC only, preceding criteria \&normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein \& urine M-protein level \<100 mg/24h; PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90% or to \<200 mg/24 hours (If disease measurable by sFLC only: VGPR \& PR: \>=90% \&\>=50% decrease in difference respectively between involved \& uninvolved sFLC levels). In addition, if present at baseline, VGPR \& PR: \>=90% \&\>=50% reduction compared with baseline in soft tissue plasmacytomas' size.

    Time frame: From treatment initiation till study completion

  22. SSB: CRR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

    CRR was defined as the percentage of participants with a BOR of confirmed sCR/CR per IMWG response criteria as determined by investigator. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).

    Time frame: From treatment initiation till study completion

  23. SSB: TTR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

    TTR was defined for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

    Time frame: From treatment initiation till study completion

  24. SSB: DOR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

    DOR (for participants (pts) with objective response (OR) per IMWG)=time from the first OR that is confirmed (conf), until conf PD per IMWG, or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest conf response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a prior lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

    Time frame: From treatment initiation till study completion

  25. SSB: DOCR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

    DOCR (for participants (pts) with CR/sCR per IMWG)= time from the first CR/sCR that is confirmed (conf), until conf PD per IMWG, or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest conf response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a prior lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

    Time frame: From treatment initiation till study completion

  26. SSB: PFS as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

    PFS=time from date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest confirmed response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a previous lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

    Time frame: From treatment initiation till study completion

  27. SSB: OS- Phase 1b Dose Escalation

    OS was defined as the time from the first date of the study intervention to the date of death due to any cause. Participants not known to have died are censored on the date of last known alive.

    Time frame: From treatment initiation till study completion

  28. SSB: MRD Negativity Rate as Per IMWG Criteria- Phase 1b Dose Escalation

    MRD negativity rate is defined as the proportion of participants with CR or better by investigator and negative MRD (assessed by central lab) per IMWG sequencing criteria at any time from the date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy, whichever occurs first. 1) CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65; 2) Sequencing MRD-negative: Absence of clonal plasma cells by next generation sequencing (NGS) on BMA in which presence of a clone was defined as \<2 identical sequencing reads obtained after DNA sequencing of BMA using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10\^5 nucleated cells.

    Time frame: From treatment initiation till study completion

  29. SSB: Pre- and Post-dose Concentrations of Elranatamab- Phase 1b Dose Escalation

    Time frame: From treatment initiation till study completion

  30. SSB: Trough Serum Concentrations of Lenalidomide- Phase 1b Dose Escalation

    Time frame: From treatment initiation till study completion

  31. SSA: Number of Participants With ADA- Phase 1b Dose Escalation

    Time frame: From treatment initiation till study completion

  32. SSB: Number of Participants With NAb- Phase 1b Dose Escalation

    Time frame: From treatment initiation till study completion

07

Results

Posted Feb 23, 2026
Limitations and caveats
Phase 2 of SSA was not conducted, based on sponsor's decision.

Participant flow

A total of 46 participants were enrolled in this study. Study had two sub-studies: sub-study A (SSA) and sub-study B (SSB). Phase 1b and Phase 2 were planned for SSA, while Phase 1b for SSB. Phase 2 of SSA was not conducted, based on sponsor's decision. Hence there is no data reported for Phase 2 in any section of the results' record.

Participant flow — Overall Study
MilestoneSSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3ASSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4ASSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1
Started261010612
Completed000000
Not completed261010612
Withdrew: Death113115
Withdrew: Withdrawal by subject132003
Withdrew: Ongoing025954

Outcome measures

PrimarySSA: Number of Participants With Dose Limiting Toxicities (DLTs)- Phase 1b Dose Escalation

DLT- Hematological:Grade (G)4 neutropenia \>5 days; febrile neutropenia; G\>=3 neutropenia, infection; G4 thrombocytopenia; G3 thrombocytopenia and G\>=2 bleeding. Non-hematological: G\>=4 adverse events(AEs); G3 cytokine release syndrome(CRS) \[except CRS not been maximally treated or improved to G\<=1 in 48 hours\]; G3 AEs (except AEs attributed to CRS, G3 nausea, vomiting, diarrhea that improve to G2\<=72 hours after maximal medical management has been initiated, G3 fatigue \< 1 week); confirmed drug-induced liver injury meeting Hy's law criteria; G3-4 laboratory abnormalities(except not associated with clinical sequelae and improve to G=\<2 in 72 hours); G2 clinically important/persistent AEs(cause significant dose delay/reduction) may be DLT; G3 injection site reaction, allergic reaction, anaphylaxis. Common Terminology Criteria for Adverse Events(CTCAE) version 5.0: G1:mild AE, G2:moderate, G3:severe, G4:life-threatening consequences; urgent intervention indicated, G5:death related to AE.

Time frame:
From Cycle 0 Day 1 through Cycle 1 Day 28 (approximately up to 35 days)
Reported as:
Count of participants · Participants
SSA: Number of Participants With Dose Limiting Toxicities (DLTs)- Phase 1b Dose Escalation
ParticipantsSSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3ASSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4A
SSA: Number of Participants With Dose Limiting Toxicities (DLTs)- Phase 1b Dose Escalation00402
PrimarySSB: Number of Participants With DLTs- Phase 1b

Hematological: G4 neutropenia \>5 days; febrile neutropenia; G\>=3 neutropenia with infection; G4 thrombocytopenia; G3 thrombocytopenia with G\>=2 bleeding. Non-hematological: G\>=4 AEs; G3 CRS (except CRS events: not been maximally treated or improved to grade \<=1 within 48 hours); G3 AEs (except: AEs attributed to CRS, G3 nausea, vomiting and diarrhea that improve to G2\<=72 hours after maximal medical management has been initiated, G3 fatigue \< 1 week); confirmed drug-induced liver injury meeting Hy's law criteria; G 3-4 laboratory abnormalities (except: not associated with clinical sequelae and improve to G=\<2 within 72 hours); Other clinically important/persistent AEs (that cause significant dose delay/reduction) may be DLT; G3 injection site reaction. CTCAE version 5.0: G1: Mild AE, G2: Moderate, G3: Severe, G4: Life-threatening consequences; urgent intervention indicated, G5: Death related to AE.

Time frame:
From Cycle 0 Day 1 through Cycle 1 Day 28 (approximately up to 42 days)
Reported as:
Count of participants · Participants
SSB: Number of Participants With DLTs- Phase 1b
ParticipantsSSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1
SSB: Number of Participants With DLTs- Phase 1b3
SecondarySSA: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Related TEAEs- Phase 1b

An adverse event was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention, including both serious and all non-serious adverse events. A serious adverse event (SAE): any untoward medical occurrence that, at any dose resulting in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. Relatedness of any AE to treatment to be judged by investigator.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Number of Participants With Severity of AEs According to Cytokine Release Syndrome (CRS) Graded According to American Society for Transplantation and Cellular Therapy (ASTCT) Grading Criteria 2019- Phase 1b

CRS: supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms must include fever at the onset, and may include hypotension, hypoxia and end organ dysfunction. As per ASTCT criteria, G1: fever (temperature \>=38 degree Celsius), hypotension and/or hypoxia none; G2: fever, hypotension not requiring vasopressors, hypoxia requiring low-flow nasal cannula/facemask or blow-by; G3: fever, hypotension requiring a vasopressor with or without vasopressin, hypoxia requiring high-flow nasal cannula/facemask, nonrebreather mask, or Venturi mask; G4: fever, hypotension requiring multiple vasopressors (excluding vasopressin), hypoxia requiring positive pressure. Organ toxicities associated with CRS graded according to CTCAE v5.0. G1: mild, G2: moderate, G3: severe, G4: life-threatening consequences; urgent intervention indicated. G5: death related to AE.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Number of Participants With Severity of AEs According to Immune Effector Cell-associated Neurotoxicity Syndrome ICANS Graded According to ASTCT Grading Criteria 2019- Phase 1b

ASTCT for ICANS \[immune effector cell-associated encephalopathy (ICE, overall score range 0-10, higher score = better condition). G1: ICE score 7-9, awakens spontaneously; G2: ICE score 3-6, awakens to voice; G3: ICE score 0-2, awakens only to tactile stimulus, any clinical seizure that resolves rapidly or non-convulsive seizures on electroencephalography that resolve with intervention, focal/local oedema on neuroimaging; G4: ICE score 0 (unarousable and unable to perform ICE), unarousable or requires vigorous or repetitive tactile stimuli to arouse. Stupor or coma, life-threatening prolonged seizure (\>5 min); or repetitive clinical or electrical seizures without return to baseline in between, deep focal motor weakness such as hemiparesis or paraparesis, diffuse cerebral oedema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI (abducens nerve) palsy; or papilledema; or Cushing's triad; G5: death.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Number of Participants With Laboratory Abnormalities- Phase 1b

Number of participants with laboratory abnormalities will be reported in this outcome measure.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Objective Response Rate (ORR) as Per International Myeloma Working Group (IMWG) Criteria as Determined by Investigator- Phase 1b

ORR: % of participants with objective response. Stringent complete response(sCR): CR \& normal serum free light chain (sFLC) ratio \&absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence. CR: negative immunofixation on serum \&urine, disappearance of soft tissue plasmacytomas \&\<5% plasma cells in BMA. If disease measurable by sFLC only, preceding criteria \&normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein \& urine M-protein level \<100 mg/24h; PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90% or to \<200 mg/24 hours (If disease measurable by sFLC only: VGPR \& PR: \>=90% \&\>=50% decrease in difference respectively between involved \& uninvolved sFLC levels). In addition, if present at baseline, VGPR \& PR: \>=90% \&\>=50% reduction compared with baseline in soft tissue plasmacytomas' size.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Complete Response Rate (CRR) as Per IMWG Criteria as Determined by Investigator- Phase 1b

CRR was defined as the percentage of participants with a Best Overall Response (BOR) of confirmed sCR/CR per IMWG response criteria as determined by investigator. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Time to Response (TTR) as Per IMWG Criteria as Determined by Investigator-Phase 1b

TTR was defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Duration of Response (DOR) as Per IMWG Criteria as Determined by Investigator- Phase 1b

DOR (for participants (pts) with objective response (OR) per IMWG)=time from the first OR that is confirmed (conf), until conf PD per IMWG, or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest conf response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a prior lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Duration of Complete Response (DOCR) as Per IMWG Criteria as Determined by Investigator- Phase 1b

DOCR (for participants (pts) with CR/sCR per IMWG)= time from the first CR/sCR that is confirmed (conf), until conf PD per IMWG, or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest conf response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a prior lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Progression Free Survival (PFS) as Per IMWG Criteria as Determined by Investigator- Phase 1b

PFS=time from date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest confirmed response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a previous lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Overall Survival (OS)- Phase 1b

OS was defined as the time from the first date of the study intervention to the date of death due to any cause. Participants not known to have died are censored on the date of last known alive.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Minimal Residual Disease (MRD) Negativity Rate as Per IMWG Criteria- Phase 1b

MRD negativity rate is defined as the proportion of participants with CR or better by investigator and negative MRD (assessed by central lab) per IMWG sequencing criteria at any time from the date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy, whichever occurs first. 1) CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65; 2) Sequencing MRD-negative: Absence of clonal plasma cells by next generation sequencing (NGS) on BMA in which presence of a clone was defined as \<2 identical sequencing reads obtained after DNA sequencing of BMA using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10\^5 nucleated cells.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Pre- and Post-dose Concentrations of Elranatamab- Phase 1b
Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Trough Serum Concentrations of Nirogacestat- Phase 1b
Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Number of Participants With Anti-drug Antibodies (ADA)- Phase 1b
Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Number of Participants With Neutralizing Antibodies (NAb)- Phase 1b
Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: Number of Participants With TEAEs and Treatment Related TEAEs- Phase 1b

AE: any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention, including both serious and all non-serious adverse events. A SAE: any untoward medical occurrence that, at any dose resulting in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. Relatedness of any AE to treatment to be judged by investigator.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: Number of Participants With Severity of Adverse Events According to CRS Graded According to ASTCT Grading Criteria 2019- Phase 1b Dose Escalation

CRS: supraphysiologic response following any immune therapy that results in the activation or engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms must include fever at the onset, and may include hypotension, hypoxia and end organ dysfunction. As per ASTCT criteria, G1: fever (temperature \>=38 degree Celsius), hypotension and/or hypoxia none; G2: fever, hypotension not requiring vasopressors, hypoxia requiring low-flow nasal cannula/facemask or blow-by; G3: fever, hypotension requiring a vasopressor with or without vasopressin, hypoxia requiring high-flow nasal cannula/facemask, nonrebreather mask, or Venturi mask; G4: fever, hypotension requiring multiple vasopressors (excluding vasopressin), hypoxia requiring positive pressure. Organ toxicities associated with CRS graded according to CTCAE v5.0. G1: mild, G2: moderate, G3: severe, G4: life-threatening consequences; urgent intervention indicated. G5: death related to AE.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: Number of Participants With Severity of Adverse Events According to ICANS Graded According to ASTCT Grading Criteria 2019- Phase 1b Dose Escalation

ASTCT for ICANS (ICE, overall score range 0-10, higher score = better condition). G1: ICE score 7-9, awakens spontaneously; G2: ICE score 3-6, awakens to voice; G3: ICE score 0-2, awakens only to tactile stimulus, any clinical seizure that resolves rapidly or non-convulsive seizures on electroencephalography that resolve with intervention, focal/local oedema on neuroimaging; G4: ICE score 0 (unarousable and unable to perform ICE), unarousable or requires vigorous or repetitive tactile stimuli to arouse. Stupor or coma, life-threatening prolonged seizure (\>5 min); or repetitive clinical or electrical seizures without return to baseline in between, deep focal motor weakness such as hemiparesis or paraparesis, diffuse cerebral oedema on neuroimaging; decerebrate or decorticate posturing; or cranial nerve VI (abducens nerve) palsy; or papilledema; or Cushing's triad; G5: death.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: Number of Participants With Laboratory Abnormalities- Phase 1b Dose Escalation

Number of participants with laboratory abnormalities will be reported in this outcome measure.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: ORR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

ORR: % of participants with objective response. sCR: CR \& normal sFLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence. CR: negative immunofixation on serum and urine, disappearance of soft tissue plasmacytomas \&\<5% plasma cells in BMA. If disease measurable by sFLC only, preceding criteria \&normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \>=90% reduction in serum M-protein \& urine M-protein level \<100 mg/24h; PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90% or to \<200 mg/24 hours (If disease measurable by sFLC only: VGPR \& PR: \>=90% \&\>=50% decrease in difference respectively between involved \& uninvolved sFLC levels). In addition, if present at baseline, VGPR \& PR: \>=90% \&\>=50% reduction compared with baseline in soft tissue plasmacytomas' size.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: CRR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

CRR was defined as the percentage of participants with a BOR of confirmed sCR/CR per IMWG response criteria as determined by investigator. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \<=4:1 or \>=1:2 for κ and λ participants, respectively, after counting \>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: TTR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

TTR was defined for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: DOR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

DOR (for participants (pts) with objective response (OR) per IMWG)=time from the first OR that is confirmed (conf), until conf PD per IMWG, or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest conf response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a prior lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: DOCR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

DOCR (for participants (pts) with CR/sCR per IMWG)= time from the first CR/sCR that is confirmed (conf), until conf PD per IMWG, or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest conf response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a prior lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: PFS as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation

PFS=time from date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurred first. PD=any of: (i)Increase (inc) \>=25% from lowest confirmed response value of (a)Serum M-component (absolute (abs) inc \>=0.5 g/dL) (b)Serum M-protein inc \>=1 g/dL if lowest M component \>=5 g/dL (c)Urine M-protein (abs inc \>=200 mg/24 h) (d)in pts without measurable (meas) serum and urine M-protein levels, difference between involved and uninvolved serum FLC levels (abs inc \>10 mg/dL) (e)in pts without meas serum and urine M-protein levels and without meas involved serum FLC, bone marrow plasma-cell (PC) percentage irrespective of baseline status (abs inc \>=10%) (ii)appearance of new lesion(s), \>=50% inc from nadir in SPD of \>1 lesion, or \>= 50% inc in longest diameter of a previous lesion \>1 cm in short axis (iii)\>=50% inc in circulating PC (minimum 200 cells per microliter) if the only measure of disease.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: OS- Phase 1b Dose Escalation

OS was defined as the time from the first date of the study intervention to the date of death due to any cause. Participants not known to have died are censored on the date of last known alive.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: MRD Negativity Rate as Per IMWG Criteria- Phase 1b Dose Escalation

MRD negativity rate is defined as the proportion of participants with CR or better by investigator and negative MRD (assessed by central lab) per IMWG sequencing criteria at any time from the date of first dose until the first documentation of confirmed PD, death or start of new anticancer therapy, whichever occurs first. 1) CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in BMA. If the only measurable disease is by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65; 2) Sequencing MRD-negative: Absence of clonal plasma cells by next generation sequencing (NGS) on BMA in which presence of a clone was defined as \<2 identical sequencing reads obtained after DNA sequencing of BMA using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10\^5 nucleated cells.

Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: Pre- and Post-dose Concentrations of Elranatamab- Phase 1b Dose Escalation
Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: Trough Serum Concentrations of Lenalidomide- Phase 1b Dose Escalation
Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSA: Number of Participants With ADA- Phase 1b Dose Escalation
Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

SecondarySSB: Number of Participants With NAb- Phase 1b Dose Escalation
Time frame:
From treatment initiation till study completion

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of study intervention and up to 90 days after last dose or start of new anticancer therapy (approximately up to 48 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 11/2 (50%)1/2 (50%)2/2 (100%)
SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 23/6 (50%)5/6 (83.3%)6/6 (100%)
SSA, Phase 1b: Elranatamab + Nirogacestat,Dose Level 33/10 (30%)6/10 (60%)10/10 (100%)
SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3A2/10 (20%)6/10 (60%)10/10 (100%)
SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4A1/6 (16.7%)4/6 (66.7%)6/6 (100%)
SSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 15/12 (41.7%)7/12 (58.3%)11/12 (91.7%)
All Participants15/46 (32.6%)29/46 (63%)45/46 (97.8%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventSSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2SSA, Phase 1b: Elranatamab + Nirogacestat,Dose Level 3SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3ASSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4ASSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1All Participants
DeathGeneral disorders1/20/60/100/100/60/121/46
Cytokine release syndromeImmune system disorders1/20/62/102/101/60/126/46
PneumoniaInfections and infestations0/22/62/100/100/62/126/46
Decreased appetiteMetabolism and nutrition disorders0/20/60/100/102/60/122/46
Disease progressionGeneral disorders0/21/61/102/100/61/125/46
Immune effector cell-associated neurotoxicity syndromeNervous system disorders0/20/60/102/100/61/123/46
DiarrhoeaGastrointestinal disorders0/20/60/101/101/60/122/46
Haemorrhoidal haemorrhageGastrointestinal disorders0/21/60/100/100/60/121/46
Chest painGeneral disorders0/21/60/101/100/60/122/46
SepsisInfections and infestations0/21/60/100/100/61/122/46
Most frequent other events
Showing 10 of 199
Most frequent other events
EventSSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2SSA, Phase 1b: Elranatamab + Nirogacestat,Dose Level 3SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3ASSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4ASSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1All Participants
NeutropeniaBlood and lymphatic system disorders2/22/67/104/105/67/1227/46
DiarrhoeaGastrointestinal disorders2/24/67/106/103/64/1226/46
HeadacheNervous system disorders2/20/62/101/101/63/129/46
NauseaGastrointestinal disorders1/25/62/105/102/63/1218/46
AnaemiaBlood and lymphatic system disorders0/23/65/104/104/68/1224/46
ThrombocytopeniaBlood and lymphatic system disorders0/24/65/101/104/64/1218/46
Aspartate aminotransferase increasedInvestigations0/22/63/100/104/61/1210/46
Decreased appetiteMetabolism and nutrition disorders0/21/63/103/104/62/1213/46
HypocalcaemiaMetabolism and nutrition disorders0/20/62/100/104/60/126/46
HypophosphataemiaMetabolism and nutrition disorders0/22/61/104/104/60/1211/46

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3ASSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4ASSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1Total
Mean61.00 ± 2.8354.67 ± 9.5867.50 ± 10.1769.60 ± 8.8367.83 ± 9.4366.33 ± 8.4965.74 ± 9.81
Sex: Female, Male
Sex: Female, Male(Participants)SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3ASSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4ASSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1Total
Female12413415
Male14693831
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3ASSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4ASSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1Total
Hispanic or Latino2310039
Not Hispanic or Latino039106937
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 1SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 2SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3SSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 3ASSA, Phase 1b: Elranatamab + Nirogacestat, Dose Level 4ASSB, Phase 1b: Elranatamab + Lenalidomide + Dexamethasone, Dose Level 1Total
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0101215
White259941039
More than one race0000000
Unknown or Not Reported0010012
08

Study locations

25 sites
  • Banner Gateway Medical Center
    Gilbert, Arizona 85234, United States
  • Banner Gateway Medical Pavilion
    Gilbert, Arizona 85234, United States
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Banner Health d.b.a. Banner MD Anderson Cancer Center
    Phoenix, Arizona 85012, United States
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • Clinical Research Advisors
    Encino, California 91316, United States
  • Clinical Research Advisors
    Los Angeles, California 90020, United States
  • Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD
    Los Angeles, California 90048, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)
    Los Angeles, California 90048, United States
  • Clinical Research Advisors
    Los Angeles, California 90048, United States
  • Cedars-Sinai Tarzana
    Tarzana, California 91356, United States
  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
    Coral Gables, Florida 33146, United States
  • University of Miami
    Coral Gables, Florida 33146, United States
  • Sylvester Comprehensive Cancer Center- Deerfield Beach
    Deerfield Beach, Florida 33442, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • UHealth Tower
    Miami, Florida 33136, United States
  • The Johns Hopkins University School of Medicine
    Baltimore, Maryland 21205, United States
  • OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231, United States
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility)
    Baltimore, Maryland 21231, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Arthur J.E. Child Comprehensive Cancer Centre
    Calgary, Alberta T2N 5G2, Canada
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Feb 2025, 39 months.

Results were first posted in Feb 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2021
First posted
Oct 25, 2021
StartActual
Oct 27, 2021
Primary completionActual
Feb 13, 2025
CompletionActual
Mar 11, 2026
Results first posted
Feb 23, 2026
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05090566
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
Oct 27, 2021
Primary completion
Feb 13, 2025
Completion
Mar 11, 2026
Results posted
Feb 23, 2026
Last update
Apr 24, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elranatamab · Nirogacestat · Lenalidomide · Dexamethasone

Start the discussion